Design and Evaluation of Small Interfering RNAs That Target Expression of the N-Methyl-d-aspartate Receptor NR1 Subunit Gene in the Spinal Cord Dorsal Horn
Open Access
- 1 September 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 322 (3) , 962-968
- https://doi.org/10.1124/jpet.107.123125
Abstract
NR1 is an essential subunit of the N-methyl-d-aspartate (NMDA) receptor, which at the spinal level is involved in injury-induced pain hypersensitivity and morphine tolerance. An in vitro luciferase assay was used to identify candidate and control (inactive) short interfering RNA (siRNA) sequences that are expressed by a recombinant adeno-associated virus (rAAV) plasmid. rAAV vectors targeting the NR1 subunit were prepared that express active or control (mismatch) siRNA sequences and injected into the mouse spinal cord dorsal horn (SCDH). Three weeks after vector administration, green fluorescent protein labeling of the ipsilateral SCDH confirmed the spatial localization of the viral transduction. Active siRNAs resulted in a 60 to 75% knockdown of NR1 mRNA and protein in the area of the virus injection. The spatial knockdown persisted for at least 6 months after a single administration of the vector. Neither the active nor the mismatch siRNAs resulted in cellular toxicity as measured by nuclear staining and cell integrity. The vector-derived knockdown of NR1 expression in SCDH did not alter acute thermal or mechanical stimulus paw-withdrawal thresholds. However, the vector-derived siRNA prevented the mechanical allodynia measured at 24 and 48 h after injection into the paw of the inflammatory agent, Complete Freund9s adjuvant. These results demonstrate that vector-derived siRNAs can be used to produce an in vivo spatial knockdown of the expression and function of the NMDA receptor that is confined to the ipsilateral SCDH. Vector-derived siRNAs may have therapeutic potential for the management of injury-induced pain resulting from the activation of NMDA receptors in the SCDH.This publication has 34 references indexed in Scilit:
- The silent treatment: siRNAs as small molecule drugsGene Therapy, 2006
- In vivo Inhibition of Hippocampal Ca2+/Calmodulin-Dependent Protein Kinase II by RNA InterferenceMolecular Therapy, 2005
- siRNAs: applications in functional genomics and potential as therapeuticsNature Reviews Drug Discovery, 2004
- Induction of an interferon response by RNAi vectors in mammalian cellsNature Genetics, 2003
- Structural variations and stabilising modifications of synthetic siRNAs in mammalian cellsNucleic Acids Research, 2003
- Phosphorylation of Extracellular Signal-Regulated Kinase in Primary Afferent Neurons by Noxious Stimuli and Its Involvement in Peripheral SensitizationJournal of Neuroscience, 2002
- A System for Stable Expression of Short Interfering RNAs in Mammalian CellsScience, 2002
- Attenuation of hyperalgesia by LY235959, a competitive N-methyl-d-aspartate receptor antagonistBrain Research, 2001
- Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegansNature, 1998
- Quantitative assessment of tactile allodynia in the rat pawJournal of Neuroscience Methods, 1994